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Summary of recent advances 
 
Inhibition of the DNA repair enzyme PARP-1 has been extensively investigated in the 
pre-clinical setting as a strategy for chemo- or radio-potentiation.  Recent evidence 
has suggested that PARP inhibitors may be active as single agents in certain rare 
inherited cancers which carry DNA repair defects.  Potent PARP-1 inhibitors have 
entered early clinical trials in cancer patients in the last 3 years and the final results of 
these trials are awaited. 
 
Introduction 
 
There has been considerable focus in recent years on the pathways of DNA repair as 
potential targets for improving cancer treatments, and inhibitors of some of these 
pathways are in early clinical development[1].  There are 5 major DNA repair 
pathways which preserve the integrity of the genome in normal cells (reviewed in [2-
4]).  Cellular DNA is repeatedly exposed to exogenous and endogenous toxins, it is 
estimated that the average rate of damage is about 104 events per cell per day [5] and 
these repair pathways are vital, with a number of inherited diseases being caused by 
mutations within them [2, 6].  However, in cancer cells, the protective effect of these 
pathways can be a disadvantage, acting as a cause of treatment resistance by 
overcoming the damage caused to tumour cells by cytotoxic agents and reducing 
cancer cell kill.  
 
Ionising radiation causes single and double strand breaks which are repaired by the 
Base Excision Repair (BER) and recombinational repair pathways respectively.  
Recombinational repair has two pathways, the error-free homologous repair (HRR) in 
dividing cells and error-prone non-homologous end joining active in G1 (NHEJ).  
These two pathways repair much of the damage caused by ionising radiation and 
chemotherapeutic agents such as cisplatin and mitomycin C.   Nucleotide excision 
repair (NER) is involved in the repair of UV damage and removal of bulky DNA 
adducts such as those caused by cross-linking agents.  The mismatch repair pathway 
(MMR) repairs replication errors and is frequently mutated in cancer cells allowing 
tolerance of such lesions [7-9].  BER is involved in the repair of single strand breaks, 
contributing to resistance to ionising radiation and alkylating agents.  O6-
alkylguanine-DNA alkyltransferase (MGMT, OGAT, ATase) is the main component 
of the Direct Repair Pathway, an efficient mechanism of DNA repair where the 
altered base is corrected without removal or disruption of the phosphodiester 
backbone.  Over expression of ATase in mammalian cells confers resistance to DNA 
alkylating agents (reviewed in [10]), and is a major factor in tumour resistance to 
these drugs. 
 
Poly (ADP-ribose) polymerase-1 (PARP-1, EC 2.4.2.30) is the most abundant 
member of a family of highly conserved enzymes discovered 4 decades ago [11].  
PARP-1 is a nuclear enzyme known to be involved in BER.  Its role as a “molecular 
nick-sensor” was elegantly described by de Murcia in 1994 [12].  Briefly PARP-1 has 
three functional domains; the DNA biding fragment (DBD) which contains two zinc 
finger motifs involved in DNA strand break recognition and a nuclear location signal, 
the central auto-modification domain which includes a BRCA-1 C-terminal domain 
(BRCT) and the C-terminal catalytic fragment which binds NAD+.  The enzyme binds 
to, and is activated by, DNA strand breaks, forming long and branched polymers of 
poly(ADP-ribose) from NAD+.  The negatively charged polymers are formed on 
various acceptor proteins, including PARP itself, histones and p53.  X-ray 
crystallography has shown that the negative charge helps open up the damaged DNA 
to allow access to other components of the repair process[12].  The polymer is rapidly 
removed by poly(ADP-ribose) glycohydrolase[13], allowing release and inactivation 
of PARP-1 to “search and signal” further DNA damage.  
 
The many in vitro experiments demonstrating that PARP-1 inhibitors potentiate the 
cytotoxicity of anti-cancer drugs and ionising radiation, and the fact that in vivo 
PARP-1 knock out mice show increased sensitivity to these agents has stimulated the 
development of specific PARP-1 inhibitors as potential chemo- and radiosensitisers 
(reviewed in [14]).  This article will focus on this area of therapeutic potential. 
 
Development of PARP inhibitors 
 
PARP-1 inhibition is an attractive method for studying the significance of this enzyme 
in biological systems and the early inhibitors were designed with this aim.  Mainly 
inhibitors have been designed around nicotinamide, which is a by-product of PARP-
mediated NAD+ cleavage, and is itself a weak PARP-1 inhibitor.  The first 
nicotinamide analogues were the benzamides.  Inhibition of PARP by 3-
aminobenzamide (3-AB) was reported over two decades ago by Whish with an 
inhibitory constant (Ki) of 1.8 ± 0.2 µM in L1210 cells [15].  The newer more potent 
PARP inhibitors have been designed based on interaction and inhibition at the NAD+ 
binding site with X-ray crystallography of inhibitors in the binding site 
complementing structure activity relationships and allowing the identification of three 
critical hydrogen bonds [14, 16, 17].   
 
As previously mentioned, part of the drive to develop potent, specific PARP inhibitors 
has been based on the observations that inhibition of PARP can potentiate the 
cytotoxicity of anticancer drugs.  Durkacz et al first reported the ADP-ribosylation 
was involved in DNA excision repair and the inhibition of the enzyme enhanced the 
cytotoxicity of demethyl sulphate, a DNA alkylating agent, in 1980.  At the end of 
this seminal paper the authors suggested that this “potentiation of cell killing by 
alkylating agents and PARP inhibitors may be of use in the treatment of human 
leukaemia” [18]. 
 
The Drug Development Programme, Northern Institute for Cancer Research, 
University of Newcastle Upon Tyne has identified, using rational drug design, 
quinazolin-4-[3H]one (e.g. NU1025) and benzimidazole-4-carboxamide(e.g. 
NU1085) derivatives which are potent inhibitors of PARP-1 [16].  NU1025 and 
NU1085 have been shown to potentiate the cytotoxicity of alkylating agents, 
bleomycin (a free-radical producing glycopeptide which causes single and double 
strand breaks) and ionising radiation in a murine leukaemia cell line (L1210) ([19]; 
[20] but not the thymidylate synthase inhibitor nolatrexed or gemcitabline (a 
nucleoside analogue).  Potentiation of camptothecan (a topoisomerase I poison) but 
not etoposide (a topoisomerase II poison) was reported in the same experimental 
system [21].  Camptothecan forms both protein-associated and non-protein associated 
single strand breaks which would bind and activate PARP-1.  Etoposide is causes the 
formation of protein-associated double strand breaks which would not be a stimulus to 
PARP-1.  The enhancement of both temozolomide and topotecan (a clinically active 
topoisomerase I poison) cytotoxicity has been confirmed in a panel of human 
common tumour cell lines independent of p53 status and tissue of origin [22]. 
Chemopotentiation of temozolomide, cisplatin and irinotecane has been demonstrated 
by the PARP-1 and PARP-2 inhibitor CEP-6800 (a 3-aminomethyl carbazole imide) 
both in tumour xenografts and cell lines [23]. Potentiation of temozolomide has also 
been reported with GPI 15427 [24] and Ino-1001 [25]. 
 
There is now considerable excitement over the potential of these agents in a wide 
variety of medical disciplines, as chemo- or radio-potentiators, as single agents in 
those cancers with other DNA repair defects and as protective agents against necrotic 
cell death in non-malignant conditions.  The oncological indications will be discussed 
below and the non-oncological potential summarised.  There are at least 3 PARP 
inhibitors in early clinical trials, AG014699 (Pfizer GRD) in combination with 
temozolomide, INO -1001 (Inotek) which is in phase II development in 
cardiovascular indication but also phase I studies with temozolomide in malignant 
glioma, and an oral compound from KuDOS which is in phase I studies as a single 
agent in cancer patients. 
 
PARP inhibition in cancer therapy as chemopotentiation 
 
There is a wealth of preclinical data that co-administration of a PARP-1 inhibitor with 
cytotoxic drugs which cause single and double strand DNA breaks potentiates the 
activity of these agents and causes persistent DNA single strand breaks[19, 22, 23, 26-
28].  Much of the pre-clinical work has focussed on potentiation of temozolomide, 
with enhanced activity seen in models inherently resistant to this agent [29-31] and it 
is in combination with this cytotoxic that PARP-1 inhibitors were taken into the clinic 
in cancer patients in 2003. 
 
AG014699 is a potent tricyclic indole PARP inhibitor which has completed both 
phase I and II studies in combination with temozolomide.  The phase I study was 
carried out in 2 stages in a collaboration between Cancer Research UK and Pfizer 
GRD.  A PARP inhibitory dose (PID) of AG014699 of 12 mg/m2/day was established 
by treating patients with advanced solid tumours with escalating doses of the PARP 
inhibitor in combination with 100 mg/m2/day temozolomide (50% of  the 
recommended dose) on a daily x5 schedule every 4 weeks.  PARP inhibition was 
measured after dosing using a validated quantifiable immunoblot in peripheral blood 
lymphocytes.  At the PID profound inhibition of the enzyme was observed for over 24 
hours after a single dose.  In the second stage of the study patients with advanced 
metastatic melanoma were treated with the PID plus escalating doses of 
temozolomide to establish the maximum tolerated dose of the combination.  All 
patients agreed to paired tumour biopsies to allow target tissue PARP-1 inhibition to 
the explored.  It proved possible to administer full dose (200 mg/m2/day) 
temozolomide in combination with this dose, achieving ~90% tumour PARP 
inhibition 5 hours after drug administration.  No toxicity specific to the PARP 
inhibitor was observed, although increasing the dose of AG014699 above 12 
mg/m2/day caused enhancement of the myelotoxicity of temozolomide.  The phase II 
recommended dose was AG014699 12 mg/m2/day with temozolomide 200 mg/m2/day 
on the above schedule and encouraging evidence of activity was seen (Plummer et al, 
paper in preparation, abstract in Proc Am Soc Clin Oncol 2005, ).  A phase II study as 
first line therapy in metastatic malignant melanoma has just completed recruitment 
and the results will be reported later this year. 
 
There are no published data so far from the on-going trials of Ino-1001 in 
combination with temozolomide in patients with malignant glioma. 
 
PARP inhibitors as radiopotentiators 
 An intriguing area of use of these agents is to potentiate radiotherapy.  Treatment with 
ionising radiation is the most widely used anticancer intervention after surgery.  
Radiotherapy damages cells by causing both single and double strand breaks and 
inducing apoptotic cell death.  DNA repair mechanisms within the cancer cells 
attempt to minimise this damage and are therefore a cause of resistance.  Once again, 
there are encouraging pre-clinical data to support this use both in cell lines [27, 32, 
33] and xenograft models [33].  This data is reinforced by the fact that PARP knock-
out animals are hypersensitive to radiation [34, 35]. 
 
Trials of PARP inhibitors with radiotherapy will be challenging in terms of defining 
endpoints to establish benefit.  Much radiotherapy is used to improve local control 
rates in the adjuvant setting, here the concerns over potentiation of local toxicity 
means dose reductions of established regimens might need to be investigated and the 
long follow-up needed are challenges to trial design. 
Radiotherapy is also used in a palliative setting where it is often very effective in a 
wide range of lesions making standardisation of response very difficult.  The 
increasing use of chemo-radiotherapy introduces another level of complexity into any 
PARP inhibitor combination studies. 
 
It is for the reasons discussed above that these novel agents have first been taken into 
the clinic in combination with chemotherapy, and trials with radiotherapy remain an 
interesting possibility at the design stage. 
 
 
Potential use as single agents in cancer therapy 
 
In the last year very exciting data have emerged suggesting that PARP inhibitors 
might be beneficial in cancer treatment as a single agent.  This would certainly have 
an advantage in terms of toxicity, as one of the concerns of chemotherapy 
combination studies is that, as well as enhancing anticancer effect, systemic PARP 
inhibition during exposure to a cytotoxic might increase myelosuppression and other 
organ toxicities. 
 
Paired papers were published in Nature last spring [36, 37] demonstrating 
hypersensitivity of both BRCA-1 and BRCA-2 homozygous mutant cell lines and 
xenografts to a PARP inhibitor alone.  The matched heterozygote and wild-type cell 
lines were not sensitive.  The proposed model for this effect is that in the dividing 
wild type and BRCA heterozygous cells any endogenous single strand breaks are 
normally rapidly repaired by BER, but when PARP is inhibited the replication fork 
will encounter persisting single strand breaks and a double strand break will be 
formed.  Despite the lack of effective BER, recombinational repair will efficiently 
correct the defect and replication continues. However, in BRCA homozygous mutant 
cells, the lack of effective recombination repair in the presence of PARP inhibition 
would lead to a collapse of the replication fork and the induction of apoptosis[38, 39]. 
 
It is these intriguing data that have led to the investigation of the KuDOS orally 
available PARP-1 inhibitor as a single anti-cancer agent, and a Phase I study is on-
going.  In addition, a phase II study of the PID of AG014699 in metastatic breast and 
ovarian cancer in proven carriers of a BRCA-1 or BRCA-2 mutation is in 
development, sponsored by Cancer Research UK. 
 
PARP inhibitors in other clinical indications 
 
One fascinating aspect of these novel agents is that there are myriad potential 
applications outside the area of cancer treatment.  In cancer medicine, the potential 
therapeutic effect is caused by inhibition of base excision repair maximising DNA 
damage and triggering the apoptotic pathway.  However, in the face of massive DNA 
damage, such as after an ischaemic episode, the activation of PARP-1 can deplete the 
cell of NAD+, causing acidosis and triggering necrotic cell death.  There are many 
pre-clinical models, utilising knock-out animals or PARP inhibitors, demonstrating 
that reduction in PARP activity in this situation is protective and minimises the 
damaged area.  Full discussion of this area is beyond the scope of this review, but 
excellent recent publications are available [32, 40-43]. 
 
Conclusions 
PARP-1 inhibition as a clinical intervention for a range of diseases has been proposed 
for many years.  In the last two years potent inhibitors have entered the clinic and data 
published so far suggest that these agents can be highly active against the target 
enzyme without inhibitor specific toxicity.  It will be a number of years before the 
true potential of this class of agents is fully known.  They may have an important 
niche outside the field of cancer; this is a very exciting drug development area to 
watch. 
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